Contact Supplier

Contact Supplier

To get in touch with Bachem AG, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    Bachem wins further major peptide supply contract

    news-releasesBachem AG
    April 14th 2023

    Bubendorf, Switzerland: – Swiss-based peptide technology specialist Bachem AG has been awarded  a five year contract worth a minimum CHF 1 billion for long term delivery of large volumes of peptides.

    This latest supply agreement, covering the five-year period from 2025 to 2029, follows on from two earlier large volume contracts announced in September 2022. In all cases, the identity of the client companies is not being disclosed to respect customer confidentiality.

    Confidence and collaboration

    Bachem CEO Thomas Meier commented: “We are very pleased about this follow-up order and the renewed confidence in our work. Long-term collaborations are important for us and our partners: they enable us to reliably plan the development and utilization of production capacities.

    “The revenues from this collaboration will help us meet our growth targets and strengthen our market leadership in peptides,” Mr. Meier added.

    Strengthening production network

    Bachem is pursuing an investment program across all sites to expand capacity that includes the modern large-scale ‘Building K’ – TIDES FABrication Plant facility at Bubendorf for the manufacture of peptides and oligonucleotides that has potential to double the manufacturing capacity at the Bachem headquarters site.

    Bachem is also building a new Swiss production site at Eiken in Aargau canton, and investing in capacity expansion across its global manufacturing network at sites in Vionnaz (Switzerland), Torrance and Vista (USA) and St. Helens (UK), with further intended strengthening of its production network from 2030 onward.

    About Bachem

    Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.

    Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.

    For further information, see


    Click on Bachem signs long-term follow-on contract for peptides to access original news release.
    Click on Bachems News to see latest News & Events.


    Bachem – Partner from Research to Marketed API

    Bachem wins further major peptide supply contract

    Bachem is strengthening its ‘tides production network to keep pace with increasing demand.

    Bachem wins further major peptide supply contract

    Bachem CEO Thomas Meier.

    Contact Bachem AG

    Simply fill out the form below to contact Bachem AG now.

    Send Bachem AG a Message